Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New York Passes Legislation To Manufacture Own Generic Drugs

The Legislation Also Covers Pay-For-Delay Agreements, Wholesale Drug Importation, And More

Executive Summary

If signed into law, New York will follow in California’s footsteps and become the second state to seek its own drug manufacturing opportunities to improve accessibility and affordability.

You may also be interested in...



'America First’ Non-Profit Points To USPTO And FDA For Patent Abuse

The America First Policy Institute has blamed patent abuse for drug unaffordability, poking holes in governmental institutions and their current systems.

Environmental Regulations May Create Barriers To Onshoring More Rx Manufacturing

The House Ways and Means Committee may take more of a kitchen sink approach to addressing drug shortages than other congressional committees that have been primarily focused on paying for quality. Hearing witnesses said Congress must follow through on funding incentives for US onshoring. 

Califf’s Top Priorities For New Year: Misinformation And Evidence Generation

FDA Commissioner is ‘pretty excited’ about obtaining high quality evidence in the postmarket space, noting agency's collaboration with NIH. He cites need to address the low cost of generic drugs as a factor in drug shortages.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel